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Abstract
Background: Controversy exists regarding the impact of CYP2D6 genotype on tamoxifen responsiveness. We examined loss of 
heterozygosity (LOH) at the CYP2D6 locus and determined its impact on genotyping error when tumor tissue is used as a DNA source.
Methods: Genomic tumor data from the adjuvant and metastatic settings (The Cancer Genome Atlas [TCGA] and Foundation 
Medicine [FM]) were analyzed to characterize the impact of CYP2D6 copy number alterations (CNAs) and LOH on Hardy 
Weinberg equilibrium (HWE). Additionally, we analyzed CYP2D6 *4 genotype from formalin-fixed paraffin-embedded (FFPE) 
tumor blocks containing nonmalignant tissue and buccal (germline) samples from patients on the North Central Cancer 
Treatment Group (NCCTG) 89-30-52 tamoxifen trial. All statistical tests were two-sided.
Results: In TCGA samples (n =627), the CYP2D6 LOH rate was similar in estrogen receptor (ER)–positive (41.2%) and ER-negative (35.2%) 
but lower in HER2-positive tumors (15.1%) (P < .001). In FM ER+ samples (n = 290), similar LOH rates were observed (40.8%). In 190 
NCCTG samples, the agreement between CYP2D6 genotypes derived from FFPE tumors and FFPE tumors containing nonmalignant 
tissue was moderate (weighted Kappa = 0.74; 95% CI = 0.63 to 0.84). Comparing CYP2D6 genotypes derived from buccal cells to FFPE 
tumor DNA, CYP2D6*4 genotype was discordant in six of 31(19.4%). In contrast, there was no disagreement between CYP2D6 genotypes 
derived from buccal cells with FFPE tumors containing nonmalignant tissue.
Conclusions: LOH at the CYP2D6 locus is common in breast cancer, resulting in potential misclassification of germline CYP2D6 
genotypes. Tumor DNA should not be used to determine germline CYP2D6 genotype without sensitive techniques to detect low 
frequency alleles and quality control procedures appropriate for somatic DNA.






The CYP2D6 enzyme metabolizes tamoxifen to its active metabo-
lites (4-hydroxy-tamoxifen and 4-hydroxy-N-desmethyl-tamox-
ifen [endoxifen]), and numerous studies have demonstrated that 
CYP2D6 genetic variants are associated with steady state endox-
ifen concentrations (1–2). However, there is substantial contro-
versy on the validity of CYP2D6 genotype as a predictor of benefit 
from tamoxifen therapy in the adjuvant setting (reviewed in [3]). 
Secondary analyses of adjuvant trials administering five years of 
tamoxifen (the North Central Cancer Treatment Group [NCCTG] 
89-30-52 [4], Arimidex, tamoxifen, alone or in combination (ATAC) 
[5], BIG1-98 [6], and the Austrian Breast and Colorectal Cancer 
Study Group [ABCSG] 8 [7] have reached discrepant conclusions). 
Multiple investigators have voiced concern regarding the unprec-
edented departure of CYP2D6 allele frequencies from Hardy-
Weinberg equilibrium (HWE) in the BIG 1-98 study (8–10). While 
substantial departure from HWE was not observed in the ABCSG 
8 analysis (7), some departure from HWE was observed with the 
CYP2D6*4 allele frequencies reported in the NCCTG 89-39-52 (4) 
and ATAC (5,9) CYP2D6 analyses. Given previous demonstra-
tion of genomic instability at the chromosomal segment where 
CYP2D6 is located (11–12), it has been hypothesized that when 
tumor DNA is used for genotyping, the presence of tumor loss of 
heterozygosity (LOH) at the CYP2D6 locus distorts the frequencies 
of observed alleles, which could lead to an excessive homozy-
gous assignment of the germline genotype (8–10). To address this 
question, we undertook a detailed evaluation of whether somatic 
LOH occurs at the CYP2D6 locus by analyzing genomic tumor 
data from the adjuvant (The Cancer Genome Atlas [TCGA]) (13) 
and metastatic settings. Furthermore, we sought to determine 
whether CYP2D6 LOH could affect the accuracy of calling ger-
mline CYP2D6 genotypes. Finally, in a limited number of adjuvant 
cases in which both formalin-fixed paraffin-embedded (FFPE) 
tumor blocks and buccal samples were available, we compared 
CYP2D6 *4 genotypes obtained from each DNA source.
Methods
Samples
Three previously published data sets were analyzed. The first 
data set included tumors collected and annotated within The 
Cancer Genome Atlas breast dataset (13). TCGA collected breast 
tumors from newly diagnosed patients who underwent surgical 
resection. Extensive quality control was employed to verify the 
presence of both tumor DNA and germline DNA. Briefly, each 
frozen primary tumor specimen had a companion normal tis-
sue DNA specimen that was derived from blood components 
(including DNA extracted at the tissue source site) (n = 684), adja-
cent normal tissue taken from greater than 2 cm from the tumor 
(n  =  76), or both (n  =  65). Each hematoxylin and eosin (H&E) 
stained case was reviewed by a board-certified pathologist to 
confirm that the tumor specimen was histologically consistent 
with breast adenocarcinoma and the adjacent normal specimen 
contained no tumor cells. The tumor sections were required to 
contain an average of 60% of tumor cell nuclei with less than 20% 
necrosis for inclusion in the study per TCGA protocol require-
ments. The clinical characteristics of this cohort and the process 
for informed consent have been previously described (13).
The second set included paraffin-embedded blocks from 
360 patients, with relapsed and metastatic ER+ (n = 261) or ER- 
(n = 99) breast cancers derived from a subset of patients from 
the NCT00780676 trial and from pathology departments of 
several medical centers, as recently described (14). From these 
samples, CYP2D6 sequencing was performed by Foundation 
Medicine (FM). In addition, samples were stained for ER, pro-
gesterone receptor (PR), and human epidermal growth factor 
receptor–2 (HER2) and reviewed by a pathologist to confirm ER 
positivity. All tissue collections were done with the approval of 
the corresponding institutional review boards, and the process 
for informed consent was previously published (14).
The third set included specimens from 190 ER-positive 
breast cancer case patients from the NCCTG 89-30-52 clinical 
trial (4). In the initial reported CYP2D6 analysis, an H&E section 
was obtained from FFPE tumors and a board-certified patholo-
gist identified the invasive component and DNA was extracted 
from a 1 cm area of highest tumor cellularity for both DNA (4) 
and RNA (15) studies. At a later date, the same tissue block was 
accessed and whole tissue sections containing both invasive 
and benign tissue were processed for DNA extraction as previ-
ously described (16–17). Additionally, germline DNA from a buc-
cal sample was collected and reported initially on 17 patients 
(4) and an additional 21 patients later provided buccal samples. 
All tissue collections were done with the approval of the cor-
responding institutional review boards, and the process for 
informed consent was previously published (4).
Genomic Analysis
For the TGCA cohort, DNA copy number at the CYP2D6 locus 
(Chr. 22: 42 522    501  – 42 525    911) was determined using the 
Affymetrix 6.0 single-nucleotide polymorphism (SNP) arrays 
(13) and copy number segmentation was performed using the 
Circular Binary Segmentation (CBS) algorithm version 1.12.0, 
as previously described (13). Copy number segments of inter-
est were identified as regions with intensity values greater than 
|0.3|. Frequency landscape plots of these segments were created 
using the SWITCHdna R-package plotting function (18). Exome 
sequencing was performed as previously described (13). Regions 
of LOH were identified using the Broad Institute’s ABSOLUTE 
method on exome sequencing data and Affymetrix 6.0 SNP 
arrays (19). LOH landscape frequency plots were created using 
modifications of SWITCHdna’s plotting function. The percent-
age of overlap between breast TCGA samples analyzed on SNP 
arrays and those through exome sequencing was 86%.
For the FM cohort, genomic DNA was extracted from 40 µm 
of FFPE tissue and up to 200 ng of extracted DNA was sheared 
by sonication, followed by ligation of Illumina sequencing adap-
tors. Sequencing libraries were hybridization captured using 
RNA-based baits (Agilent), targeting a total of 3320 exons of 182 
cancer-related genes and 78 polymorphisms in 34 ADME-related 
genes. Deep (>500x) paired-end sequencing (49 x 49 cycles) was 
performed using the HiSeq2000 (Illumina). Sequence reads were 
mapped to the reference human genome (hg19), analyzed for all 
classes of genomic alterations (substitutions, indels, and copy 
number alterations), using custom methods optimized for clini-
cal tumor specimens with stromal admixture. Variant calls at 
the CYP2D6 locus were resolved into genotypes according to the 
star (*) allele nomenclature (20). If the minor allele frequency 
was greater than 5%, the patient was considered to have ger-
mline heterozygosity. To determine tumor LOH at CYP2D6, a 
genome-wide copy number model was fitted to the coverage 
data at all sequenced exons and more than 1800 SNPs. This 
profile was segmented and interpreted using allele frequencies 
of sequenced SNPs to estimate tumor purity and copy number 
at each segment. Fitting was performed using Gibbs sampling, 
assigning total copy number and minor allele count to all seg-
ments. LOH was called if total copy number at the CYP2D6 locus 
was 1 (copy loss LOH), or if copy number was 2 or more with a 






minor allele count of 0 (copy neutral LOH). The distortion of the 
germline alternate allele frequency from 50% because of LOH is 
calculated. To assess the impact of LOH, we simulated low-sen-
sitivity genotyping assays by requiring minor allele frequencies 
to have minimum levels of 10% and 20% before assigning geno-
types as heterozygous. The estimate of potential error impact 
on genotyping methods was then estimated using the HWE test.
For the NCCTG samples, CYP2D6 genotyping (*3, *4, *6, *10, *41) 
was performed at the Mayo Clinic using the Applied Biosystems’ 
Taqman Allelic Discrimination Assay (Foster City, CA), as previ-
ously described and reported in the context of a pooled analysis 
of NCCTG and Stuttgart patients (16) and as submitted to the 
International Tamoxifen Pharmacogenomics Consortium (21). 
Analyses were performed irrespective of ethnicity.
Statistical Methods
Within the TCGA, a Pearson’s Chi Square Test was used to deter-
mine whether LOH rates differed across intrinsic subtypes. 
Within the FM cohort, a two-sided Fisher’s exact test was used 
to assess whether copy loss rate differed with respect to ER sta-
tus. Within the NCCTG cohort, the extent of agreement between 
CYP2D6 genotypes derived from FFPE tumor and FFPE tumors 
containing nonmalignant tissue was assessed using weighted 
Kappa statistics and the corresponding 95% confidence inter-
val. HWE tests were calculated using an exact test (the Simple 
Hardy-Weinberg Calculator by Michael H Court) (http://www.
tufts.edu/~mcourt01/Documents/Court%20lab%20-%20HW%20
calculator.xls) by comparing the observed and expected geno-
type frequencies for case patients and control patients. All sta-




Using SNP array data (n  =  728) (13), evaluation of the CYP2D6 
locus at chromosome 22 demonstrated copy number altera-
tions (CNA) in 29.0% (n = 211) (Figure 1A). Among the 627 case 
patients with exome sequencing data, 219 case patients (34.9%) 
had LOH at the CYP2D6 locus (Figure 1B). While the CNA were 
higher for the ER-positive (35.0%) (Figure  2A) compared with 
the ER-negative (12.0%) (Figure 2B), LOH rates were similar com-
paring ER-positive (41.2%) (Figure  3A) and ER-negative (35.2%) 
(Figure 3B). Analyzing according to intrinsic subtypes, LOH rates 
among the ER+ (luminal A [40.3%] luminal B [42.7%]) and basal-
like (43.4%) subsets were similar but greater than that in the 
HER2-enriched subtype (15.1%) (P < .001, Pearson’s Chi Square 
Test). For each of these subtypes, a “zoomed-in plot” of the 
region containing the CYP2D6 gene is indicated (Supplementary 
Figures 1 and 2, available online). A further analysis within the 
clinically defined HER2+ subset demonstrated that LOH rates 
were lower within the ER-/HER2+ (14.3%) compared with ER+/
HER2+ (26.6%).
Foundation Medicine Samples
The findings among the case patients comprising the FM 
cohort were similar to those from the TCGA cohort, where 82 of 
201(40.8%) and 23 of 89 (25.8%) of the ER+ and ER- case patients, 
respectively, had LOH at the CYP2D6 locus (Figure 4). While copy-
neutral LOH was similar in both ER+ and ER- (18.9% and 19.1%, 
respectively), the copy loss rate among ER+ case patients was 
statistically significantly greater relative to ER- case patients 
(21.9% vs 6.7%; P = .001, two-sided Fisher’s exact test).
Given that standard genotyping assays (eg, Taqman) may 
not be able to detect an allele that is present at low frequency 
because of LOH, CYP2D6 genotypes were determined using next 
generation sequencing (Table 1) and the potential effect of LOH 
on CYP2D6 genotype was assessed (Table 2). Among the 105 case 
patients with LOH, a substantial fraction had a low frequency 
of one of the germline alleles: under 20% (n  =  27), under 10% 
(n = 7). If such samples were assumed to be homozygous, this 
would result in excessive number of homozygotes and, statisti-
cally, departure from HWE (Table 2).
NCCTG 89-30-52 Samples
The original CYP2D6  *4 genotyping results were derived from 
tumor FFPE (FFPE-T) and demonstrated departure from HWE 
(chi square  =  16.1, P ≤ .001) (4). These case patients (n  =  190) 
were reassessed using FFPE sections containing nonmalignant 
tissue (FFPE-NM) (16). For CYP2D6 *4, the agreement was mod-
erate comparing CYP2D6 *4 genotypes derived from FFP-T with 
FFPE-NM (weighted Kappa 0.74; 95% CI = 0.63 to 0.84), resulting 
in excess homozygous genotypes and departure from HWE (P 
< .001). Specifically, 15 original homozygous wild-type (Wt/Wt) 
cases were reclassified as heterozygous for *4 (Wt/*4) and three 
homozygous variant (*4/*4) were reclassified as (Wt/*4). The *4 
discrepancies among the remaining five cases were likely unex-
plained by LOH (Table 3). An evaluation for HWE using the geno-
typing data derived from FFPE-NM demonstrated that CYP2D6*4 
is within HWE (chi square = 1.34, P = .25).
To further investigate the observed discrepancy between 
these results, the CYP2D6 genotypes derived from FFPE-T tumor 
(4) and FFPE-NM (16) were compared with CYP2D6*4 genotype 
derived from buccal cells (germline). Among the 31 case patients 
with both FFPE-T and buccal cells available for CYP2D6*4 gen-
otyping, there were six (19.4%) cases of disagreement. In four 
of these six case patients, CYP2D6  *4 genotypes classified as 
homozygous wild-type using FFPE-T were determined to be het-
erozygous for *4 (Wt/*4) using DNA derived from buccal cells, 
and, in another case, a homozygous variant (*4/*4) based on 
FFPE-T was classified as (Wt/*4) using DNA from buccal cells. 
One of the errors appeared to be unrelated to LOH, as the tumor-
derived genotype of *4/*4 was classified as Wt/Wt using buccal 
cells. In contrast, among the 35 case patients with DNA from 
both FFPE-NM and buccal cells, there was 100% agreement com-
paring CYP2D6 *4 genotypes from each source.
Discussion
Using two large breast cancer datasets, we have demonstrated 
the presence of extensive LOH at the CYP2D6 locus in breast 
cancer. Furthermore, our data demonstrate that determination 
of germline CYP2D6 genotype using cancer tissue can result 
in substantial departure from HWE, as was seen in the origi-
nal NCCTG CYP2D6 analysis (4), ATAC (5), and BIG 1-98 (6) stud-
ies. In the cohorts examined in this study, CYP2D6 genotyping 
using DNA extracted from FFPE-T blocks resulted in erroneous 
classification of up to 40% of CYP2D6*4 heterozygotes (interme-
diate metabolizers) as either extensive metabolizers or poor 
metabolizers.
Recently, Rae et al., in a cohort of 122 patients, extracted DNA 
from three 0.6-mm diameter cores obtained from FFPE breast 
tumor blocks as well as DNA derived from either normal lymph 
nodes or leukocytes (22). Rae et al. used DNA from these sources 






to genotype for CYP2D6 and demonstrated a concordance rate of 
over 94% between these different sources, concluding that this 
modest quality control study was sufficient to support the use 
of breast cancer tissue for germline genotyping of CYP2D6 (22). 
The results of our studies in this report clearly refute the con-
clusions of Rae and colleagues and provide further confirmation 
of the concerns raised by multiple authors (8–10) regarding the 
fidelity of the CYP2D6 genotyping performed in the context of 
the BIG 1-98 study (6).
Quality control procedures are critical for accurate genotyp-
ing. This includes a requirement to develop assays for all rel-
evant variants, particularly for a locus as complex as CYP2D6 
(23). An additional critical aspect of quality control relates to the 
source of DNA used for germline genotyping. In ATAC (5), FFPE 
tumor blocks from the trans-ATAC tumor collection were used 
for DNA extraction. In BIG 1-98 (6), DNA was extracted from one 
or two 1 mm cores that were punched into an area of the FFPE 
block most representative of the invasive tumor component.
Given our observation of LOH at the chromosomal locus con-
taining CYP2D6, it was critical to understand whether the use of 
tumor DNA could contribute to the observed departures from 
HWE. In the FM cohort, nearly one-third of the tumors with LOH 
had a frequency of the germline allele under 20%, suggesting that 
use of a low-sensitivity polymerase chain reaction (PCR) assay 
could result in misclassification of heterozygous CYP2D6 geno-
types as homozygous. Therefore, we directly compared CYP2D6 
genotyping results from different laboratories using DNA from 
the same patients. In the original publication of the NCCTG 
89-30-52 clinical trial, CYP2D6 genotyping (using DNA extracted 
from tumors) was performed in the laboratory of Rae et al. at 
the University of Michigan (4). When CYP2D6 genotyping was 
repeated at the Mayo Clinic using DNA derived from the same 
FFPE blocks but using whole tissue sections containing benign 
tissue, genotyping errors were identified, which appeared to be 
partially related to the lack of detection of low-frequency alleles 
in the 2005 analysis; however, additional discrepancies were 
observed that appear to be unrelated to LOH (Table  3). A  full 
reanalysis of the NCCTG data set demonstrated that CYP2D6 
genotypes met HWE, with complete agreement (35/35) between 
the updated genotype results with the germline (buccal) cells in 
those patients that provided a buccal sample. Furthermore, as 
previously reported, CYP2D6 genotype was statistically signifi-
cantly associated with the risk of recurrence (16,21).
In ATAC (5), the departure from HWE with regard to CYP2D6 *4 
was similar in magnitude as observed in the original NCCTG 
CYP2D6 analysis (HWE χ2 = 18.1, P =  .000021). While we are con-
fident in our conclusions that LOH at the CYP2D6 locus is com-
mon in breast cancer and that the use of tumor DNA for CYP2D6 
genotype results in misclassification of germline CYP2D6 genotype, 
we were unable to reproduce the extreme departure from HWE 
observed in BIG 1-98 (P = 10-92) (6). Stanton noted that if LOH was 
the sole cause of deviation from HWE in BIG 1-98, the distorted 
genotype frequencies could be normalized by adjusting for LOH (9). 
Therefore, we agree with Stanton that the extreme departure from 
HWE in BIG 1-98 may be related to other factors, such as the use of 
nonstandard PCR techniques (use of upwards of 60 PCR cycles (6).
Following the simultaneous publication of the CYP2D6 anal-
yses of the ATAC and BIG 1-98 data sets, the authors of these 
studies argued that testing for CYP2D6 has no value in clinical 
practice, and an accompanying editorial concluded that this 
matter can be likely laid to rest (24). However, our findings have 
validated the initial concerns raised by multiple investigators 
Figure 1. Cytochrome P450 2D6 (CYP2D6) copy number alterations (A) and loss of heterozygosity (B) within the entire Cancer Genome Atlas cohort. CNA = copy number 
alteration; LOH = loss of heterozygosity.






regarding genotyping error (8–10) and the conclusions that were 
generated based on these erroneous data. It is now clear that 
data from ongoing prospective clinical trials will be necessary 
to settle the debate on whether or not CYP2D6 genotyping can 
identify patients in whom tamoxifen would be would be an infe-
rior therapy. However, until such data are available, clinicians 
and patients should be aware of the data generated from sec-
ondary analyses of prospective clinical trials that support the 
importance of both CYP2D6 genotype (7,16) and endoxifen con-
centrations (25) and that these data fulfill the basic criteria of 
Simon et  al. for a “prospective-retrospective” design in which 
the biomarker test is analytically and preanalytically validated 
for use with archived tissue (26).
An important finding within the TCGA CYP2D6 analysis was 
the observation of a substantially higher rate of LOH within the 
luminal A (40%), luminal B (43%), and basal-like subsets (40%), 
compared with the HER2-enriched (15%) and normal-like (8%) 
subtypes. Within the clinically defined HER2+ subset, LOH rates 
were lower within the ER-/HER2+ (14%) compared with ER+/
HER2+ (27%). Within the FM cohort, the CYP2D6 loss rate among 
ER+ case patients was statistically significantly greater relative 
to ER- case patients While the biological relevance of these find-
ings is unknown, the demonstration of substantial LOH at chro-
mosome 22q13, the cytogenetic segment which contains the 
CYP2D6 gene, has been implicated in breast (11), colon (11,27), 
and insulinomas (28), suggesting that a putative tumor suppres-
sor gene in this region may be important in the pathogenesis of 
cancer, and particularly in the luminal and basal-like subtypes 
of breast cancer.
There are some limitations to our study. While we have 
demonstrated that the use of tumor-derived DNA contributes 
to CYP2D6 genotyping error (analytical validity), this is unlikely 
to be the only factor contributing to the heterogeneity in the 
tamoxifen CYP2D6 literature. In addition to “analytical validity,” 
Simon et al. pointed out that an “adequate number of patients 
with archived tissue must be present,” and suggested that the 
correlative study “include at least two-thirds of the total accrued 
patients” (26). It should be noted that in the ATAC study, less 
than 19% of the patients receiving tamoxifen were analyzed 
with regard to CYP2D6 genotype. Lastly, Simon et al. pointed out 
the critical nature of “clinical validity” (26). Here, it should be 
noted that the tamoxifen CYP2D6 literature contains variability 
in tamoxifen dosing (20-40 mg/day), duration of therapy (one to 
10 years), ER status of the primary tumor, use of CYP2D6 inhibit-
ing medications, and, finally, lack of control for drugs that alter 
the hazard for recurrence (chemotherapy and aromatase inhibi-
tors) (21). Therefore, we recommend careful control for each of 
these factors when analyzing and interpreting the tamoxifen 
CYP2D6 literature.
In summary, we have provided definitive data from inde-
pendent data sets that over 40% of primary and metastatic 
breast tumors exhibit tumor LOH at the CYP2D6 locus and that 
the use of standard PCR (eg, Taqman) genotyping techniques 
applied to purified tumor DNA to detect germline CYP2D6 vari-
ation results in genotyping error because of an excess num-
ber of homozygotes and departure from HWE. Based on these 
results, we recommend that CYP2D6 genotyping be repeated in 
those studies in which the use of tumor DNA to derive germline 
Figure 2. Cytochrome P450 2D6 (CYP2D6) copy number alterations within The Cancer Genome Atlas estrogen receptor (ER)–positive (A) and ER-negative (B) cohorts. 
CNA = copy number alteration; ER = estrogen receptor.






CYP2D6 genotype resulted in substantial departure from HWE. 
Furthermore, recommendations and/or guidelines for the use 
of CYP2D6 genotyping should not be derived from studies with 
evidence for genotyping error.
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